Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.

BACKGROUND/AIMS: HIV and hepatitis C virus (HCV) share common modes of transmission, resulting in about 33% incidence of coinfection among people infected with HIV. The survival benefit from highly effective antiretroviral therapy (HAART) for HIV infection is resulting in an increased incidence of hepatocellular carcinoma (HCC) in this population. There are no reports to date regarding the coadministration of HAART and sorafenib for hepatocellular carcinoma. METHODS: We report the case of a 42-year-old male patient coinfected with HIV and HCV who developed advanced HCC not amenable to curative therapy. The patient was treated with sorafenib, an oral multikinase inhibitor shown to lead to a longer median survival time and time to progression in patients with advanced HCC. Antiretroviral therapy was continued during sorafenib therapy. RESULTS: The patient achieved a partial tumor response after 3 months and continued to respond at subsequent assessments. His serum alpha-fetoprotein normalized from 2,172 IU/ml to 2 IU/ml. He had durable stable disease after 23 months of therapy. Antiretroviral therapy was efficacious (CD4(+) lymphocyte count, 377/microl; HIV viremia, <50 copies/ml). The simultaneous administration of these therapies was well tolerated. No grade 3 or 4 toxicities were observed. Exacerbation of pre-existing hypertension, grade 2 diarrhea, and grade 1 skin reaction were observed. CONCLUSIONS: This is the first report in which sorafenib has been successfully used to treat HCC in a patient with HIV-HCV coinfection.

Contribution of imaging to the evaluation of pyomyositis.

PURPOSE: To analyse the fundamental features of each imaging modality with the aim of defining their contribution to the diagnosis of pyomyositis. MATERIALS AND METHODS: We retrospectively reviewed 10 observations collected between 1997 and 2004, 5 of paravertebral muscles and 5 of the muscles of the limbs. Imaging was carried out with US (8/10 observations) and/or CT (9/10 observations), and/or MRI (6/10 observations). The pathogen was isolated in 6/10 observations. RESULTS: The imaging criteria for the detection and characterization of pyomyositis are based on three pathological phases: an invasive phase characterized by inflammatory oedema, a suppurative phase characterised by abscess development, and a late phase featuring the distant spread of the infection. Based on these interpretation criteria, pyomyositis was correctly diagnosed with US in 5/8 observations, with CT in 9/9 observations and with MR in 5/6 observations. Four false-negative cases were found. CONCLUSIONS: Since the clinical symptoms of pyomyositis are often insidious and delayed, an integrated imaging approach may be very useful for diagnosing this condition.